Since AKT inhibitor and ERK1/2 inhibitor also abolish the IGF-1 signaling, for anti-ER drug-resistant tumor with an elevated AGR2 level, our study also indicated that targeting IGF-1/AGR2 pathway might be a treatment strategy. Here, ESR1 is linked to neoplasm.